Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, S. Zhang et al.|Annals of Oncology|2021Cited by 724
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Francesco Cognetti, Sabino De Placido et al.|The Lancet|2015Cited by 201
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerationsA. D'Arienzo, Filippo Montemurro, Annarita Verrazzo et al.|EClinicalMedicine|2023Cited by 90
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcomeLinda Cucciniello, Fabio Puglisi, Giovanna Garufi et al.|Cancer Treatment Reviews|2023Cited by 58
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, Francesca Poggio et al.|The Lancet Oncology|2022Cited by 50